LUCD · Lucid Diagnostics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $1.21M | $1.16M | $828.0K | - | $1.17M | $976.0K | $1.00M | - |
| Cost of Revenue | $1.55M | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.21M | - | $1.27M | $1.25M | $1.43M | - | $1.67M | $1.37M | $1.50M | - |
| SG&A | $5.43M | - | $5.61M | $5.62M | $6.16M | - | $5.36M | $4.87M | $4.07M | - |
| Total Operating Expenses | $13.37M | - | $12.97M | $12.55M | $13.31M | - | $12.87M | $12.17M | $11.79M | - |
| D&A | $222.0K | - | - | - | $221.0K | - | - | - | $501.0K | - |
| Operating Income | ($12.11M) | - | ($11.76M) | ($11.38M) | ($12.49M) | - | ($11.69M) | ($11.19M) | ($10.79M) | - |
| Interest Expense | $9.0K | - | $2.0K | $6.0K | $9.0K | - | $1.0K | $6.0K | $12.0K | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($13.91M) | - | ($10.40M) | ($4.44M) | ($26.91M) | - | ($12.37M) | ($11.01M) | ($10.61M) | - |
| EPS - Basic | ($0.17) | - | ($0.10) | ($0.08) | ($0.52) | - | ($0.25) | ($0.23) | ($0.40) | - |
| EPS - Diluted | - | - | ($0.10) | ($0.08) | ($0.52) | - | ($0.25) | ($0.23) | ($0.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.88M | $34.70M | $47.33M | $31.12M | $25.24M | $22.36M | $14.49M | $24.92M | $24.77M | $18.90M |
| Accounts Receivable | $689.0K | $643.0K | $550.0K | $373.0K | $61.0K | $45.0K | $39.0K | $160.0K | $49.0K | $45.0K |
| Inventory | $469.0K | $353.0K | $486.0K | $505.0K | $484.0K | $341.0K | $651.0K | $683.0K | $410.0K | $278.0K |
| Accounts Payable | $1.08M | $970.0K | $751.0K | $833.0K | $829.0K | $1.24M | $1.14M | $903.0K | $969.0K | $1.15M |
| Current Assets | $31.36M | $37.47M | $49.84M | $33.83M | $27.54M | $25.15M | $16.82M | $27.95M | $27.58M | $22.07M |
| Total Assets | $34.08M | $40.45M | $53.20M | $38.67M | $32.80M | $30.71M | $22.60M | $34.11M | $32.05M | $27.27M |
| Current Liabilities | $29.39M | $28.58M | $26.21M | $29.43M | $36.57M | $23.52M | $14.25M | $15.98M | $19.98M | $29.38M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $30.08M | $29.51M | $27.36M | $30.81M | $38.17M | $25.32M | $16.26M | $18.13M | $20.15M | $29.58M |
| Stockholders' Equity | $4.00M | $10.94M | $25.84M | $7.86M | ($5.38M) | $5.39M | $6.34M | $15.98M | $11.89M | ($2.31M) |
| Retained Earnings | ($297.96M) | ($274.33M) | ($258.07M) | ($247.67M) | ($239.78M) | ($203.77M) | ($192.22M) | ($179.85M) | ($168.85M) | ($150.74M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.10M) | - | - | - | ($12.46M) | - | - | - | ($12.61M) | - |
| Investing Cash Flow | ($215.0K) | - | - | - | ($93.0K) | - | - | - | ($37.0K) | - |
| Financing Cash Flow | $5.49M | - | - | - | $15.44M | - | - | - | $18.52M | - |
| CapEx | $215.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($12.32M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -971.0% | -978.8% | -1508.1% | - | -997.8% | -1146.7% | -1078.1% | - |
| EBITDA margin | - | - | - | - | -1481.4% | - | - | - | -1028.1% | - |
| Net margin | - | - | -858.5% | -381.7% | -3249.8% | - | -1055.5% | -1127.6% | -1060.1% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.89 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 105.0% | 107.9% | 172.5% | - | 142.2% | 140.6% | 150.0% | - |
| SG&A / Revenue | - | - | 462.8% | 483.0% | 744.2% | - | 456.9% | 498.7% | 406.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -40.8% | - | -19.5% | -11.5% | -82.0% | - | -54.7% | -32.3% | -33.1% | - |
| Return on equity | -347.7% | - | -40.2% | -56.5% | 500.4% | - | -195.2% | -68.9% | -89.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.07 | 1.31 | 1.90 | 1.15 | 0.75 | 1.07 | 1.18 | 1.75 | 1.38 | 0.75 |
| Quick ratio | 1.05 | 1.30 | 1.88 | 1.13 | 0.74 | 1.05 | 1.14 | 1.71 | 1.36 | 0.74 |
| Cash ratio | 0.95 | 1.21 | 1.81 | 1.06 | 0.69 | 0.95 | 1.02 | 1.56 | 1.24 | 0.64 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1346.0x | - | -5879.5x | -1897.3x | -1387.4x | - | -11694.0x | -1865.3x | -899.3x | - |
| Equity multiplier | 8.52 | 3.70 | 2.06 | 4.92 | -6.10 | 5.70 | 3.57 | 2.13 | 2.69 | -11.80 |
| Liabilities / Assets | 0.88 | 0.73 | 0.51 | 0.80 | 1.16 | 0.82 | 0.72 | 0.53 | 0.63 | 1.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.02 | 0.03 | 0.03 | - | 0.05 | 0.03 | 0.03 | - |
| Inventory turnover | 3.31 | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 166d | 117d | 27d | - | 12d | 60d | 18d | - |
| Days inventory outstanding | 110d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 253d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 4.2x | 14.5x | - | - | 6.5x | 2.5x | 3.1x | - |
| P / S | - | - | 90.2x | 97.9x | 123.8x | - | 35.0x | 40.5x | 36.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 3.3% | 19.2% | -17.3% | - | 49.7% | 513.8% | 124.4% | - |
| Revenue CAGR (3y) | - | - | 151.6% | - | 63.6% | - | 80.3% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 3.0% | - | -0.6% | -1.7% | -15.7% | - | -5.1% | 3.4% | 24.6% | - |
| Net income growth (YoY) | 48.3% | - | 16.0% | 59.7% | -153.6% | - | 12.9% | 3.3% | 34.7% | - |
| EPS growth (YoY) | - | - | 60.0% | 65.2% | -30.0% | - | 26.5% | 14.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 102.9% | 307.6% | -50.8% | - | - | 148.0% | 6.0% | -52.2% | - |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Lucid Diagnostics Inc. against the 5 most active filers in the same SIC group.